Adjuvant systemic therapy trades a reduction in recurrence risk against side effects incurred by everyone treated, most of whom would not have relapsed. When the survival gain is small - as it is for many adjuvant regimens - the severity and duration of those effects are not a footnote to the decision, they are most of it.
Common Sense Oncology and the EORTC propose a specific change in what gets reported. Instead of mean quality-of-life scores over time, which flatten individual experience and hide how long harm lasts, publications should report the proportion of treated patients experiencing a prespecified deterioration on a validated scale, and how long that deterioration persists both during treatment and after it ends. Assessment should cover symptoms, functioning domains and overall quality of life. Between-group comparisons should target outcomes defined as key by oncologists and by patients, with descriptive reporting across the remaining domains. Quality-of-life data should appear in the primary report, not a later paper, and be updated long-term to capture lasting deficits.
The reason this is a practice changer rather than a methods note is what it makes sayable in clinic. "One in four patients had a meaningful deterioration in function that lasted more than six months" is a sentence a patient can weigh against a 3% absolute gain. A mean score difference is not. This is a recommendation to trialists; nothing changes in what you can quote until trials adopt it.
- Ask of any adjuvant trial what proportion of patients deteriorated and for how long, not the mean score.
- Quote absolute recurrence benefit alongside duration of harm when consenting for adjuvant therapy.
- Quality-of-life data appearing only in a later companion paper is a reporting weakness worth noticing.
- Long-term reporting matters most for adjuvant therapy, where survivors live with the deficit.
- This is guidance to trialists; current published trials mostly do not report this way.
Why it matters
It converts quality-of-life data into a form a patient can actually weigh against a small absolute survival gain.
Read the rest in the app
You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.
Scan to keep reading on your phone. No account needed to start.
Tomorrow morning, before your first patient
One edition a day for oncology, written by the desk, every claim tied to its paper. Six minutes.
Get the app — free